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GROUP COMPONENT PROTEIN-DERIVED MACROPHAGE ACTIVATING FACTOR (GcMAF) 
STIMULATES MACROPHAGES THAT INDUCE HUMAN BREAST CANCER CELL APOPTOSIS 	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MATERIALS and METHODS 
ü  Highly purified, activity-tested GcMAF was obtained from Immuno Biotech Ltd, 
Guernsey, Channel Isles. Common reagents were from Sigma Aldrich (Milan, Italy). 
ü  Cell lines. Human breast cancer cells (cell line MCF-7) were obtained from the Istituto 
Zooprofilattico Sperimentale della Lombardia e dell?Emilia-Romagna, Brescia, Italy. In 
experiments of co-cultures, macrophages (cell line Raw 264.7, HPA Culture Collection) 
were activated by culturing them in the same medium of MCF-7 cells and in the presence 
of 100 ng/ml GcMAF for 72 h prior to addition to the MCF-7 cell culture. Gc-protein was 
used as control. The macrophages were added at a ratio of 1:1 to the MCF-7 cell culture. 
ü  Study of cell morphology. Cell morphology was studied by phase-contrast microscopy 
using an Optika inverted microscope (Model XDS-2; Optika Microscopes, Bergamo, 
Italy).  
	  
A human breast cancer cell in the centre of the 
image is surrounded by small round GcMAF-
activated macrophages. The nucleus of the 
macrophages is well stained.  The cytoplasm of 
macrophages appears vacuolized thus 
suggesting active phagocytosis. 
	  
Human breast cancer cells 
surrounded by hundreds of 
GcMAF-activated macrophages. 
	  
The nucleoli of the human 
breast cancer cell can be 
recognized; this phenomenon 
can be interpreted as an index of 
remaining synthetic activity as 




deconstruct the cytoplasm of the 
large human breast cancer cell in 
the centre of the image. 
	  
GcMAF-activated macrophages 
deconstruct the cytoplasm of the 
human breast cancer cells in the 
centre of the image. 
	  
G c M A F - a c t i v a t e d 
macrophages deconstruct 
the cytoplasm of the human 
breast cancer cells in the 
centre of the image. The 
fragmented chromatin in the 
nuclei of the cancer cells 
can be observed. 
Another field of observation 
where human breast cancer cells 
surrounded by hundreds of 
GcMAF-activated macrophages 
can be observed. 
	  
Ø  Our results demonstrate that GcMAF stimulates macrophages that 
in turn attack human breast cancer cells, deconstruct their 
assembly and eventually phagocytise them.  
Ø  These results are consistent with the observation that macrophages 
infiltrated experimental tumours implanted in severely 
immunodeficient mice after GcMAF injections (J Surg Res. 2012 
Jan;172(1):116-22).  
Ø  However, at variance with the observation reported above, in our 
experiments we could rule out indirect effects due to the adaptive 
response of the whole organism to the presence of an advanced 
tumour and to the GcMAF-induced inhibition of angiogenesis 
with consequent tumour hypoxia and necrosis (J Surg Res. 2012 
Jan;172(1):116-22).  
	  
Ø  Taken together these results are consistent with clinical reports 
describing the therapeutic efficacy of GcMAF in human breast 
cancer patients. 
The observation reported here confirm and extend the results 
presented in (Int J Cancer. 2008 Jan 15;122(2):461-7; Cancer 
Immunol Immunother. 2008 Jul;57(7):1007-16; Transl Oncol. 
2008 Jul;1(2):65-72; J Med Virol. 2009 Jan;81(1):16-26; Autism 
Insights 2012:4 31–38; Anticancer Res. 2013 Jul;33(7):2917-9), 
and open the way to further studies aimed at assessing the role 
and indications of GcMAF in the immunotherapy of cancer and 
other chronic diseases.  
ü  The first publication on GcMAF in a peer-reviewed journal 






ü  In this article, a group of researchers from the Temple 
University School of Medicine in Philadelphia, USA, 
described the effects of a protein, defined as GcMAF, on rat 
macrophages.   
ü  In 2008 it was demonstrated that GcMAF treatment was 
effective against metastatic breast cancer with reported 
eradication of tumors and no recurrence for more than 4 
years (Int J Cancer. 2008 Jan 15;122(2):461-7). 
ü  We recently demonstrated (Anticancer Res. 2012 Jan;32(1):
45-52) that the anticancer efficacy of GcMAF can be 
ascribed to different effects: 
1.  Direct inhibition of human breast cancer cell proliferation 
and reversion of the transformed phenotype. 
2.  Inhibition of human breast cancer cell-induced 
angiogenesis. 
3.  Stimulation of tumoricidal macrophages. 
 
ü  GcMAF activates macrophages that infiltrate experimental 
tumours in animal models (Oncol Lett. 2011 Jul;2(4):
685-691. J Surg Res. 2012 Jan;172(1):116-22.).  
ü  This evidence, however, refers to experimental tumors other 
than human breast cancer.  
ü  Therefore, in order to fill this gap of knowledge, we 
performed experiments to provide clear-cut evidence that 
GcMAF, as part of the vitamin D axis, activates normal 
macrophages that in turn exert a tumoricidal action against 
human breast cancer cells.  
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